Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | Director · Chief Executive Officer | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,050,249 |
Ending reported balance
After 2026-09-22 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-22 · Sale · Disposed 1,000 · Balance 1,074,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 2 · 2026-09-22 · Sale · Disposed 2,000 · Balance 1,072,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 3 · 2026-09-22 · Sale · Disposed 9,300 · Balance 1,062,949 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 4 · 2026-09-22 · Sale · Disposed 9,900 · Balance 1,053,049 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Row 5 · 2026-09-22 · Sale · Disposed 2,800 · Balance 1,050,249 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 27 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 27 F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 213,250 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 213,250 F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 71,644 |
Reported balance
Holding disclosure · report date 2026-09-22 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 71,644 F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F6: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F7: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F8: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F9: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,800 | $82.37 | $230,622.00 |
DisclosureSEC source: 0001610717-26-000421 · form4.xml · nonDerivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,050,249 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $82.28 to $82.53, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,900 | $81.83 | $810,071.46 |
DisclosureSEC source: 0001610717-26-000421 · form4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,053,049 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $81.28 to $82.25 inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,300 | $80.90 | $752,400.69 |
DisclosureSEC source: 0001610717-26-000421 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,062,949 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $80.28 to $81.27, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,000 | $79.62 | $159,239.00 |
DisclosureSEC source: 0001610717-26-000421 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,072,249 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $79.11 to $80.07, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 22, 2026 Filed Sep 24, 2026 20:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,000 | $78.23 | $78,228.40 |
DisclosureSEC source: 0001610717-26-000421 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,074,249 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.75 to $78.73, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:19 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000396 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,075,249 Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 19:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 492 | $64.75 | $31,855.28 |
DisclosureSEC source: 0001610717-26-000393 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,075,349 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.59 to $64.99, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 19:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,494 | $63.98 | $415,465.34 |
DisclosureSEC source: 0001610717-26-000393 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,075,841 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.56 to $64.54, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 19:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 3,500 | $63.02 | $220,580.15 |
DisclosureSEC source: 0001610717-26-000393 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,082,335 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.53 to $63.50, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 20:46 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 18,545 | $63.02 | $1,168,774.52 |
DisclosureSEC source: 0001610717-26-000392 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,085,835 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000386 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,104,380 Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,661 | $36.16 | $60,069.40 |
DisclosureSEC source: 0001610717-26-000293 · form4.xml · nonDerivative · entry 4 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,108,380 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $35.98 to $36.24, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,821 | $35.32 | $346,837.45 |
DisclosureSEC source: 0001610717-26-000293 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,110,041 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $34.86 to $35.82, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,991 | $34.28 | $342,506.47 |
DisclosureSEC source: 0001610717-26-000293 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,119,862 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.76 to $34.71, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:22 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 8,527 | $33.29 | $283,855.30 |
DisclosureSEC source: 0001610717-26-000293 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,129,853 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.75 to $33.74, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,718 | $24.71 | $264,833.21 |
DisclosureSEC source: 0001610717-26-000164 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,138,380 F2 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $24.45 to $24.88, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 22, 2026 Filed May 27, 2026 21:57 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 18,175 | $24.44 | $444,224.26 |
DisclosureSEC source: 0001610717-26-000164 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,149,098 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 20:07 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,000 | $24.56 | $122,784.00 |
DisclosureSEC source: 0001610717-26-000145 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,167,273 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.49 to $24.70, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,000 | $19.52 | $97,611.50 |
DisclosureSEC source: 0001610717-26-000134 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,172,273 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $19.49 to $19.59, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 10,000 | $19.13 | $191,297.00 |
DisclosureSEC source: 0001610717-26-000134 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,177,273 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.78 to $19.41, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · balance_after: Reflects the transfer by the Reporting Person of 13,644 shares of Class A Common Stock to the Y/S Pot Trust on March 3, 2026. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000086 · form4.xml · nonDerivative · entry 3 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200,917 Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,860 | $23.18 | $43,111.27 |
DisclosureSEC source: 0001610717-26-000086 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,203,667 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.15 to $23.25, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:14 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 14,292 | $22.67 | $323,985.35 |
DisclosureSEC source: 0001610717-26-000086 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,205,527 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.15 to $23.145, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:24 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 157,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000077 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,219,819 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2026, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,632 | $18.58 | $178,927.88 |
DisclosureSEC source: 0001610717-26-000070 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,061,924 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 32,537 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001610717-26-000003 · form4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,600 Underlying: Class A Common Stock · 32,537 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 17,463 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001610717-26-000003 · form4.xml · derivative · entry 5 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 17,463 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All of the shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:52 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 50,000 | $1.20 | $60,000.00 |
DisclosureSEC source: 0001610717-26-000003 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,071,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 22:23 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 13,261 | $19.00 | $251,936.46 |
DisclosureSEC source: 0001610717-25-000398 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,021,556 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 20:37 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000341 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,034,817 Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 20:15 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,348 | $13.79 | $128,880.88 |
DisclosureSEC source: 0001610717-25-000321 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 945,892 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 22:31 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000199 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 955,240 F1 · balance_after: Reflects transfer of 88,955 shares to Sirius Trust and 35,430 shares to Y/S Pot Trust on June 5, 2025. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 21:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000147 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,080,625 Read SEC document |
| May 22, 2025 Filed May 27, 2025 21:08 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 9,343 | $8.30 | $77,540.36 |
DisclosureSEC source: 0001610717-25-000144 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,083,625 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:35 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 171,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000075 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,092,968 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/12th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2025, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001610717-25-000049 · form4.xml · derivative · entry 7 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,463 Underlying: Class A Common Stock · 50,000 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: This option, originally for 300,000 shares, of which 282,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 50,000 | $1.20 | $60,000.00 |
DisclosureSEC source: 0001610717-25-000049 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 921,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:50 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 7,942 | $10.63 | $84,393.28 |
DisclosureSEC source: 0001610717-25-000049 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 871,540 F1 · kind: The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 12, 2024 and terminated effective March 4, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.415 to $10.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 22:42 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,092 | $11.07 | $56,346.04 |
DisclosureSEC source: 0001610717-25-000036 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 879,482 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 23, 2024 Filed Dec 24, 2024 01:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001610717-24-000554 · form4.xml · derivative · entry 6 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,463 Underlying: Class A Common Stock · 12,000 shares Expires 2027-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option, originally for 300,000 shares, of which 232,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021. Read SEC document |
| December 23, 2024 Filed Dec 24, 2024 01:29 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 12,000 | $1.20 | $14,400.00 |
DisclosureSEC source: 0001610717-24-000554 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 21:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,693 | $13.69 | $91,612.45 |
DisclosureSEC source: 0001610717-24-000530 · form4.xml · nonDerivative · entry 2 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 872,574 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000530 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 879,267 Read SEC document |
| November 14, 2024 Filed Nov 18, 2024 21:43 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000524 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 881,117 Read SEC document |
| August 22, 2024 Filed Aug 26, 2024 21:05 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 6,749 | $22.53 | $152,052.95 |
DisclosureSEC source: 0001610717-24-000455 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 882,467 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:06 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 425 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000271 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 889,216 Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,877 | $24.30 | $118,528.66 |
DisclosureSEC source: 0001610717-24-000258 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 889,641 F1 · kind: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 21:17 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantClass A Common Stock | 88,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000186 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,518 F1 · shares: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/16th of the RSUs shall vest on each quarterly anniversary measured from February 21, 2024, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 23:02 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GiftClass A Common Stock | 1,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000163 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,664 F1 · balance_after: Reflects transfer of 29,900 shares to Y/S Descendants' Trust and 6,250 shares to Y/S Pot Trust on March 14, 2024. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 21:12 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,660 | $44.00 | $205,020.89 |
DisclosureSEC source: 0001610717-24-000135 · form4.xml · nonDerivative · entry 1 Saxonov Serge · CIK 0001786720 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,900 F1 · price: This transaction was executed in multiple trades at prices ranging from $43.9600 to $44.0401. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.